Is Tesofensine FDA approved?
No. This profile records Tesofensine as not FDA approved and for research use only.
MORE CONTEXT ›
Review the regulatory and source details on this page for the current context.
THE APPETITE CRUSHER
TE-1; NS2330
Tesofensine is a triple monoamine reuptake inhibitor that was originally developed for Parkinson's and Alzheimer's. It blocks reuptake of dopamine, norepinephrine, and serotonin, powerfully reducing appetite and increasing energy expenditure. In trials it produced greater weight loss than any other single agent, making it one of the most effective compounds for obesity.
Not FDA approved · research use only
Reviewed by our clinical team
1 research sources
Sep 1, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
No. This profile records Tesofensine as not FDA approved and for research use only.
Review the regulatory and source details on this page for the current context.
Dose: 0.25-0.5 mg orally once daily.
Schedule: daily. Cycle: Ongoing with medical supervision. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 1 curated or current research sources.
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Blocks DAT, NET, and SERT transporters
Increases monoamines in hypothalamic feeding centers
Enhances sympathetic activity and energy expenditure
Improves dopamine-mediated focus and motivation
The live research feed did not return papers for this page. The curated references below remain available for crawlable source context.